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Abstract
Background and purpose Current demographic changes indicate that more people will be care-dependent due to increasing 
life expectancy. Little is known about impact of preexisting dependency on stroke outcome after endovascular treatment 
(EVT).
Methods We compared prospectively collected baseline and outcome data of previously dependent vs. independent stroke 
patients (prestroke modified Rankin Scale score of 3–5 vs. 0–2) treated with EVT. Outcome measures were favorable 3-month 
outcome (mRS ≤ 3 for previously dependent and mRS ≤ 2 for independent patients, respectively), death and symptomatic 
intracranial hemorrhage (sICH).
Results Among 1247 patients, 84 (6.7%) were dependent before stroke. They were older (81 vs. 72 years of age), more often 
female (61.9% vs. 46%), had a higher stroke severity at baseline (NIHSS 18 vs. 15 points), more often history of previous 
stroke (32.9% vs. 9.1%) and more vascular risk factors than independent patients. Favorable outcome and mortality were to 
the disadvantage of independent patients (26.2% vs. 44.4% and 46.4% vs. 25.5%, respectively), whereas sICH was compa-
rable in both cohorts (4.9% vs. 5%). However, preexisting dependency was not associated with clinical outcome and mortal-
ity after adjusting for outcome predictors (OR 1.076, 95% CI 0.612–1.891; p = 0.799 and OR 1.267, 95% CI 0.758–2.119; 
p = 0.367, respectively).
Conclusion Our study underscores the need for careful selection of care-dependent stroke patients when considering EVT, 
given a less favorable outcome observed in this cohort. Nonetheless, EVT should not systematically be withheld in patients 
with preexisting disability, since prior dependency does not significantly influence outcome.
Keywords Ischemic stroke · Endovascular treatment · Dependency · Disability · Outcome
Background and purpose
Current demographic changes indicate that an increasing 
number of people will need external help in their daily 
life, given the rising life expectancy and incidence of care 
dependency among older people in Western countries 
[1]. As an example, an estimated 3.4 million people will 
be care-dependent in Germany by 2030 [2]. Concurrently, 
stroke has reached epidemic proportions worldwide [3] 
and endovascular treatment (EVT) is an approved and pre-
ferred intervention to achieve reperfusion in large cerebral 
artery occlusions [4, 5]. However, little is known about the 
impact of preexisting dependency on stroke outcome treated 
with EVT as patients with modified Rankin Scale (mRS) 
score ≥ 2 were excluded from latest randomized trials [5]. 
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Thus, current guidelines recommend a prestroke mRS score 
0–1 for patients being considered for EVT [6, 7]. We aimed 
to assess the clinical outcomes in care-dependent stroke 
patients treated with EVT.
Patients and methods
This study was based on the Bernese stroke center database, 
a systematic prospective registry of consecutive patients 
with ischemic stroke treated at the Stroke Center of Uni-
versity Hospital of Berne, Switzerland. It was approved by 
the Local Ethics Committee Bern. For this study, we ana-
lyzed all stroke patients who underwent EVT (mechanical 
thrombectomy and/or intraarterial thrombolysis (IAT) with 
urokinase) between January 2005 and December 2016. 
Requests for access to the dataset from qualified research-
ers trained in human subject confidentiality protocols may be 
sent to Department of Neurology, University Hospital Berne 
(marcel.arnold@insel.ch). The following variables were pro-
spectively collected as defined previously [8–10]: age, sex, 
prestroke mRS score, arterial hypertension, diabetes mel-
litus, hyperlipidemia, smoking status, history of coronary 
artery disease and previous stroke, antithrombotic medica-
tion at stroke onset, stroke onset-to-treatment time and stroke 
etiology according to the Trial of ORG 10172 in Acute 
Stroke Treatment (TOAST) criteria. Clinical stroke sever-
ity was assessed by a stroke neurologist at admission using 
the National Institutes of Health Stroke Scale (NIHSS) score 
[11]. Preexisting dependency was defined as prestroke mRS 
score 3–5, whereas patients with a prestroke mRS score 0–2 
were classified as independent. We performed EVT accord-
ing to our institutional guidelines as described before [12]. 
According to our local practice, prestroke dependency was 
not a strict exclusion criterion for EVT in acute ischemic 
stroke as we assumed that dependent patients with large ves-
sel occlusion may also benefit from EVT. However, final 
treatment decision was individualized on a case-by-case 
basis at the discretion of the interdisciplinary team of neu-
rologists and neuroradiologists. Patients were treated with 
intra-arterial urokinase, mechanical interventions, or both. 
Patients within 4.5 h after symptom onset were additionally 
treated with intravenous thrombolysis (IVT) [7]. All patients 
treated with EVT were admitted to intermediate or intensive 
care unit for at least 24 h. Brain imaging with MRI or CT 
was systematically performed 24 h after intervention and 
in any case of clinical deterioration. Symptomatic intracra-
nial hemorrhage (sICH) was defined according to ECASS 
II criteria [13]. Primary outcome measures were as follows: 
(1) favorable clinical outcome at 3 months (mRS score ≤ 2 
in independent patients and mRS score ≤ 3 in dependent 
patients), (2) death within 3 months and (3) occurrence of 
sICH. The endpoints were prospectively assessed during 
hospital stay and at 3-month outpatient visits.
Statistical analysis
We compared demographic and baseline characteristics 
between prestroke dependent and independent patients 
using Fisher exact test for dichotomous variables and Wil-
coxon rank-sum test for continuous variables in univariate 
analyses. The independent effect of prestroke dependency on 
endpoints was assessed in a multivariable logistic regression 
model. Any variable with p < 0.1 in the univariate analysis 
was entered into the regression model. Age and baseline 
NIHSS score were entered as mandatory into the model 
because they have been proven to be independent predictors 
of clinical outcome after stroke [14]. All tests were two-
sided and the level of statistical significance was set to 0.05. 
Statistical analyses were performed using the statistical soft-
ware R (version 3.1.2; R Core Team [2014]; R: A Language 
and Environment for Statistical Computing; R Foundation 
for Statistical Computing, Vienna, Austria).
Results
A total of 1247 patients were eligible for this study. Of these, 
84 (6.7%) were previously dependent. Baseline characteris-
tics of both groups are detailed in Table 1. When compared 
with independent patients, those with prestroke dependency 
were older (81 vs. 72 years; p < 0.0001), more often female 
(61.9% vs. 46%; p = 0.0063), suffered more often from 
diabetes mellitus (31% vs. 15.9%; p = 0.0013) and arterial 
hypertension (79.8% vs. 67.6%; p = 0.0207). Furthermore, 
dependent patients had more often a history of previous 
stroke (32.9% vs. 9.1%; p < 0.0001) and pretreatment with 
antithrombotics (65.1% vs. 42.6%; p = 0.0001). Baseline 
NIHSS score was slightly higher in dependent patients (18 
vs. 15 points; p = 0.0113), whereas stroke etiology and time 
from stroke onset to EVT did not significantly differ between 
both groups.
Clinical outcomes are summarized in Table  2. At 
3 months, dependent patients less often reached favorable 
outcome (26.2% vs. 44.4%; p = 0.0013) and had higher mor-
tality rates (46.4% vs. 25.5%; p < 0.0001) than independent 
patients, whereas sICH did not significantly differ between 
the groups (4.9% vs. 5%; p = 1.000).
For multivariable regression analyses, the following 
covariates were entered into the model: age, sex, depend-
ency status, baseline NIHSS score, arterial hypertension, 
diabetes mellitus, pre-stroke use of antithrombotics, and his-
tory of previous stroke. After adjusting for these covariates, 
dependency status was no more associated with favorable 
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outcome (odds ratio [OR], 1.076; 95% confidence interval 
[CI], 0.612–1.891; p = 0.799), mortality (OR, 1.267; 95% 
CI 0.758–2.119; p = 0.367), or sICH (OR, 1.124 95% CI 
0.380–3.324; p = 0.833).
Discussion
This study examined the impact of pre-existing dependency 
on stroke outcome after EVT and revealed some impor-
tant findings. First, the rate of care-dependent patients 
undergoing EVT in our cohort was similar as compared with 
a large multicenter study investigating intravenous throm-
bolysis (IVT) in 7430 stroke patients (6.7% vs. 6.6%) [15]. 
This rate is also similar to the proportions reported in large 
trials of SITS-EAST and SITS-MOST, meaning that the 
willingness to thrombolyse care-dependent stroke patients 
has not increased [16, 17]. Thus, care-dependent patients 
constitute still a minor but existent subgroup for stroke phy-
sicians in their daily clinical work [18]. However, their pro-
portion may markedly increase in near future with respect 
to the recent demographic changes, which again underlines 
Table 1  Baseline characteristics 
according to prestroke 
dependency status in patients 
treated with endovascular 
treatment
IQR indicates Interquartile Range; NIHSS National Institutes of Health Stroke Scale; OTT onset to treat-
ment time
Prestroke dependent (mRS 3–5) Prestroke inde-
pendent (mRS 
0–2)
Dependent vs 
independent
Value Value p value
Age, y, median (IQR) 81 (73.75–85) 72 (60–79)  < 0.0001
Female sex (%) 52/84 (61.9) 535/1163 (46.0) 0.0063
Baseline NIHSS score, median (IQR) 18 (11–21) 15 (10–19) 0.0113
Arterial hypertension (%) 67/84 (79.8) 784/1160 (67.6) 0.0207
Diabetes mellitus (%) 26/84 (31.0) 185/1161 (15.9) 0.0013
Hyperlipidemia (%) 43/82 (52.4) 661/1147 (57.6) 0.3583
Smoking (%) 9/64 (14.1) 237/1063 (22.3) 0.1595
Coronary Artery Disease (%) 14/82 (17.1) 217/1154 (18.8) 0.771
History of previous stroke (%) 27/82 (32.9) 105/1158 (9.1)  < 0.0001
Pre-stroke use of antithrombotics (%) 54/83 (65.1) 491/1153 (42.6) 0.0001
OTT [min], median (IQR) 276.5 (199.5–352.25) 272 (209–363) 0.5836
Cause of stroke 0.1325
 Large artery atherosclerosis (%) 5/84 (6) 170/1163 (14.6)
 Cardiac embolism (%) 41/84 (48.8) 485/1163 (41.7)
 Small artery disease (%) 0/84 (0) 1/1163 (0.1)
 Other determined cause (%) 3/84 (3.6) 69/1163 (5.9)
 Undetermined cause (%) 35/84 (41.7) 438/1163 (37.7)
Table 2  Outcome according to prestroke dependency status in patients treated with endovascular treatment
OR indicates odds ratio; CI confidence interval; sICH symptomatic intracranial hemorrhage; NIHSS National Institutes of Health Stroke Scale
* Adjusted for age, sex, dependency status,  baseline NIHSS score, arterial hypertension, diabetes mellitus, pre-stroke use of antithrombotics, 
and history of previous stroke **Good outcome was defined as 3-month modified Rankin scale (mRS) score 0–3 for previously care-dependent 
patients and mRS score 0–2 for previously independent patients
Outcome measures
Prestroke dependent 
[n/N (%)]
Prestroke independent 
[n/N (%)]
p value
Unadjusted [OR, 95% CI]
p value
Adjusted* [OR, 95% CI]
Death at 3 months 39/84 (46.4) 297/1163 (25.5)  < 0.0001 0.367*
[2.525 (1.567 – 4.049)] [1.267 (0.758 – 2.119)]
Good outcome at 3 months** 22/84 (26.2) 516/1163 (44.4) 0.0013 0.799*
[0.445 (0.257 – 0.746)] [1.076 (0.612 – 1.891)]
sICH 4/81 (4.9) 57/1133 (5) 1 0.833
[0.980 (0.252 – 2.755)] [1.124 (0.380 – 3.324)]
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the role of this study [19]. In line with this, the proportion 
of care-dependent stroke patients undergoing treatment with 
EVT was higher (11%) according to a recently published 
multicenter study [20]. Second, care-dependent patients in 
our cohort had a higher burden of vascular risk factors that 
are associated with poor stroke outcome: they were older, 
had more severe stroke and more cardiovascular risk factors 
(e.g., arterial hypertension and diabetes mellitus) and up to 
one-third had already suffered from stroke before as com-
pared to independent patients. These findings are in line with 
other studies reporting unbalanced baseline characteristics to 
the disadvantage of care-dependent stroke patients [15, 21, 
22]. Third, dependent patients had less often a favorable out-
come and a higher mortality risk as compared to independ-
ent patients (26.2% vs 44.4% and 46.4% vs. 25.5%, respec-
tively). However, dependency status was not associated with 
clinical outcomes after adjusting for potential confounders. 
Thus, the unfavorable outcome in dependent patients is prob-
ably related to the differences at baseline (e.g., older age 
and stroke severity) and higher disease burden as mentioned 
above and not to the dependency status itself [23, 24]. It has 
been shown that the likelihood of favorable stroke outcome 
after EVT linearly decreases with age [25–27]. Furthermore, 
older patients with pre-stroke dependency may have a higher 
susceptibility for medical complications such as pneumo-
nia and medical care may be more often withdrawn after 
thrombolysis according to patient’s preferences [15, 28]. Of 
note, the outcome of pre-dependent stroke patients with-
out thrombolysis is worse in any case as untreated stroke 
patients with pre-existing dependency were reported to have 
a 2.2-fold higher mortality risk than independent patients 
[29–31]. Therefore, EVT should not be systematically 
withdrawn in care-dependent patients. Our results suggest a 
careful selection of care-dependent patients for EVT and an 
accurate adjusting of patient and family expectations with 
respect to the outcomes. Leker and colleagues reported that 
stroke patients with pre-existing disability treated with EVT 
may have a 4.4-fold increased risk for poor clinical outcome 
(mRS ≥ 4). However, the study size was rather small (23 
dependent vs. 108 independent patients) and definition of 
outcomes different than in our study [32]. Goldhoorn and 
colleagues analyzed data of 157 dependent stroke patients 
from MR CLEAN registry and reported results that were 
very similar to our study [20]. Favorable outcome was seen 
in 27% of prestroke-dependent patients, compared with 
42% of prestroke-independent patients (p < 0.05) [20]. After 
adjustment, prestroke dependency was not associated with 
less-favorable outcome, whereas intracranial bleeding risk 
was similar in both groups.[20] However, the authors defined 
3-month favorable outcome as mRS 0–2 or not worsening 
of the mRS score [20]. In comparison, we routinely used a 
dichotomized classification of prestroke mRS either as 0–2 
(independent) or 3–5 (care-dependent) rather than using a 
continuous numerical score for prestroke mRS. Thus, pre-
stroke care-dependent patients with 3-month mRS 4 or 5 
were not able to achieve favorable outcome (defined as 
mRS ≤ 3) in our study. We therefore assume that the rate 
of care-dependent stroke patients achieving favorable out-
come after EVT may have been even higher in our study 
by applying the same outcome definition as reported from 
MR CLEAN trial [20]. Instead, we used a predefined slid-
ing dichotomy analysis for favorable outcome (mRS 0–2 
for independent patients vs. mRS 0–3 for care-dependent 
patients) as recommended for outcome assessment in unbal-
anced cohorts with varying prognostic factors [33]. Of 
note, literature on EVT in care-dependent stroke patients is 
sparse as care-dependent patients have been excluded from 
randomized controlled studies yet [34–37]. Karlinski and 
colleagues investigated 7250 stroke patients treated with 
IVT and reported that patients with prestroke dependency 
(mRS ≥ 3) were less likely to achieve favorable outcome at 
3 months despite IVT  (ORadjusted 0.59; 95% CI 0.34–1.01; 
p = 0.055) [22]. In addition, dependency status was inde-
pendently associated with mortality in both large IVT trials 
[15, 22]. In view of these results, one may speculate whether 
care-dependent patients with acute stroke might benefit more 
from EVT than IVT, but a firm conclusion is not possible 
due to lack of comparative studies. This is especially of 
relevance as dependent patients had a higher stroke sever-
ity (as measured by baseline NIHSS score) in our study as 
compared to the two abovementioned IVT trials, while EVT 
has been shown to be more effective treatment of severe 
stroke due to large vessel occlusion than IVT [5, 15, 22, 38]. 
Another interesting finding of our study is that the risk of 
sICH in care-dependent patients was not increased as com-
pared to the counterpart (4.9% vs. 5%) although bleeding 
predictors such as older age, higher stroke severity, history 
of previous stroke and increased use of antithrombotics at 
stroke onset were distributed to the disadvantage of depend-
ent patients [27, 39–43]. The risk of sICH in our cohort 
was also comparable to the bleeding risk in care-dependent 
patients treated with IVT (4.8%) and lower than in MR 
CLEAN registry (8%) [15, 44]. Thus, the unfavorable out-
comes in dependent patients are not related to an excess of 
intracranial bleeding complications and EVT seems to be 
safe in care-dependent patients.
The main strength of this study is the high data quality 
due to systematic and prospective data collection at base-
line and 3 months by certified neurologists. Assessment of 
the data, therefore, is unlikely to have been influenced by 
the current research question. Nevertheless, we are aware 
of several limitations.
First, this is a non-randomized observational study 
including a relatively small sample size of dependent stroke 
patients with unbalanced baseline characteristics in both 
cohorts. Second, a selection and treatment bias is likely in 
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view of the observational study design and may not be com-
pletely removed through multivariate model. Thus, we urge 
to a cautious interpretation of our findings. Third, we were 
not able to assess the exact causes of pre-stroke dependency 
and the exact mRS score in dependent patients. Fourth, data 
were collected over 10 years during which incremental steps 
in stroke treatment were implemented. Especially recanaliza-
tion techniques and acute stroke care treatment like stroke 
unit care and early rehabilitation might influence outcome 
in stroke patients. Nevertheless, EVT has a long tradition in 
our center and has been systematically performed. Finally, 
the rating of prestroke mRS might be challenging due to a 
high degree of interobserver variability [45, 46].
Conclusion
This study revealed unfavorable outcomes in care-depend-
ent stroke patients after EVT and suggests a careful patient 
selection for EVT. However, prestroke dependency should 
not be a reason to withhold EVT in these patients as out-
come was rather related to unfavorable baseline differences 
in dependent patients (e.g., older age, higher stroke sever-
ity, history of previous stroke) and was not determined by 
the dependency status itself. Furthermore, EVT seems to be 
safe in care-dependent stroke patients with respect to similar 
risk of sICH in both cohorts. A well-powered randomized-
controlled trial would be ideal to assess the safety and effi-
cacy of EVT in care-dependent patients and to identify the 
patients who benefit most from EVT.
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